Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees

Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease

Masoud Dara1, Ivan Solovic2, Giovanni Sotgiu3, Lia D’Ambrosio4,5, Rosella Centis4, Delia Goletti6, Raquel Duarte7, Stefano Aliberti8, Fernando Maria de Benedictis9, Graham Bothamley10, Tom Schaberg11, Ibrahim Abubakar12, Brian Ward13, Vitor Teixeira13, Christina Gratziou14 and Giovanni Battista Migliori4

Affiliations: 1World Health Organization Office at the European Union, Brussels, Belgium. 2National Institute for TB, Lung Diseases and Thoracic Surgery, Vyse Hagy, Catholic University Ruzomberok, Ruzomberok, Slovakia. 3Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy. 4WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri IRCCS, Tradate, Italy. 5Public Health Consulting Group, Lugano, Switzerland. 6National Institute for Infectious Diseases, Rome, Italy. 7EPI Unit, Institute of Public Health, University of Porto, Porto, Portugal. 8School of Medicine and Surgery, University of Milan–Bicocca, UO Clinica Pneumologica, AO San Gerardo, Monza, Italy. 9Paediatric Italian Society, Section Marche, Ancona, Italy. 10Dept of Respiratory Medicine, Homerton University Hospital NHS Foundation Trust, London, UK. 11Dept of Pneumology, Deaconess Hospital Rotenburg, Rotenburg [Wümme], Germany. 12Centre for Infectious Disease Epidemiology, UCL and Tuberculosis Section, Public Health England, London, UK. 13European Respiratory Society, EU Affairs Dept, Brussels, Belgium. 14University Respiratory Medicine Unit, Evgenidio Hospital, Athens, Greece.

Correspondence: Giovanni Battista Migliori, WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese 21049, Italy. E-mail: giovannibattista.migliori@fsm.it

ERS and the European Region of The Union call for prioritisation of TB care, prevention and control among refugees

Tuberculosis (TB) is a major cause of mortality from an infectious disease, globally affecting 9.6 million cases, with 1.5 million deaths in 2014 [1]. In 2014, there were 273 381 TB cases reported in the World Health Organization (WHO) European region, and an estimated 33 000 deaths [2]. Vulnerable populations (i.e. individuals affected by discrimination, hostility or economic adversity), which often include migrants and refugees, have an increased risk of suffering from TB disease [1, 3, 4]. If this is not efficiently addressed, the exposure of these groups to Mycobacterium tuberculosis strains may lead to a rise in the number of cases of disease and related deaths, as well as contributing to a further increase in drug-resistant TB cases.

Several factors have contributed to the increase of population mobility in the WHO European region [3]. This rise in the level of cross-border movement has increased the need for collaboration between national...
health systems. Sustainable and effective mechanisms are thus needed to coordinate interventions to ensure quality-based prevention, diagnosis and treatment for TB and latent TB infection (LTBI) [5, 6]. These interventions represent both individual human rights (independent of legal or residential status of the subject) and public health pre-requisites to control and eliminate TB, as well as to prevent further development of multidrug-resistant (MDR)-TB and extensively drug-resistant TB [7, 8].

For undocumented migrants, there is an urgent need for policies that will facilitate easy access to TB diagnosis and treatment, as well as stop deportation until the end of treatment. These interventions would be both in the interest of the individual and of the community in terms of TB control and elimination [9–13]. In 2015, more than one million migrants and refugees reached Europe by land and sea. In the whole of 2014, the figure was much lower (219 000) [4, 14]. In spite of the resolutions and statements recently released by WHO and the European Union [4, 15], little is known about the policies in force in the different countries in Europe to manage TB and LTBI among refugees [16, 17].

The following points should be noted. 1) The refugees’ health is an integral part of the health of the wider community, as well as a human right [3, 9]; 2) TB is neither highly virulent nor easily transmitted, and is treatable, and therefore efforts should be implemented to detect and treat it promptly. Provision of treatment is essential to break the transmission cycle. 3) Refugees who come from middle or high TB incidence countries, as well as those from low TB incidence countries who have travelled and lived in precarious conditions, have a higher risk of being infected and of developing TB than the population of the host country [1, 3, 5, 6]. 4) The diagnosis of LTBI, TB and MDR-TB is not always easy to organise and perform in the centres hosting refugees upon arrival in Europe [4, 16, 17] or as they travel through other countries. 5) Sub-optimal medical management of LTBI, TB and MDR-TB and/or inadequate follow-up of this mobile population could undermine TB prevention and control among refugees and the host society [3, 9].

The European Respiratory Society and the European Region of the International Union Against TB and Lung Disease urge health authorities, national and international technical agencies and civil society organisations, as well as donor agencies, to prioritise TB care, prevention and control. They strongly recommend: 1) adapting and implementing the principles of the WHO End TB Strategy to ensure adequate prevention, diagnosis and treatment of TB (and of LTBI in the countries where these are offered) among refugees [1, 5]; 2) providing quality surveillance, monitoring and evaluation, and operational research to enhance TB prevention, control and care among refugees; 3) ensuring timely screening for active TB among refugees coming from middle or high TB incidence countries; 4) avoiding stigmatisation and stereotypes of both TB-infected people and vulnerable groups; 5) promoting universal access to prevention, diagnosis and treatment services for LTBI (in the countries where these are offered) and TB, as well as to the necessary care of existing comorbidities [1, 5]; and 6) ensuring quality infection control, including protective measures for staff, and providing HIV testing and counselling to detect HIV and TB/HIV co-infected individuals [18, 19].

References